{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Male+Urogenital+Diseases&page=16",
    "query": {
      "condition": "Male Urogenital Diseases",
      "page": 16
    },
    "page_size": 10
  },
  "pagination": {
    "page": 16,
    "page_size": 10,
    "total_count": 11199,
    "total_pages": 1120,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Male+Urogenital+Diseases&page=17&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Male+Urogenital+Diseases&page=15&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T16:27:06.470Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00919113",
      "title": "Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Interstitial Cystitis",
        "Painful Bladder Syndrome"
      ],
      "interventions": [
        {
          "name": "2% sodium chondroitin sulfate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Watson Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 98,
      "start_date": "2009-07",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2013-05-03",
      "last_synced_at": "2026-10-15T16:27:06.470Z",
      "location_count": 20,
      "location_summary": "Boulder, Colorado • Denver, Colorado • Farmington, Connecticut + 17 more",
      "locations": [
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Wellington",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00919113"
    },
    {
      "nct_id": "NCT04258813",
      "title": "Onco-primary Care Networking to Support TEAM-based Care",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Blood Pressure",
        "Hypertension",
        "Cancer",
        "Cancer, Breast",
        "Cancer of Prostate",
        "Cancer Colorectal",
        "Cancer, Endometrial",
        "Cancer of Head and Neck",
        "Non Small Cell Lung Cancer",
        "CVD - Cardiovascular Disease",
        "Diabetes Mellitus",
        "Hypercholesterolemia",
        "Diabetes",
        "Cancer of Esophagus",
        "Cancer of Liver",
        "Cancer, Renal Cell",
        "Cancer of Pancreas",
        "Cancer Ovaries"
      ],
      "interventions": [
        {
          "name": "iGuide Intervention (Self-guided)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "iGuide 2 Intervention (Tailored/Targeted)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Control",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 313,
      "start_date": "2021-06-14",
      "completion_date": "2026-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-20",
      "last_synced_at": "2026-10-15T16:27:06.470Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04258813"
    },
    {
      "nct_id": "NCT00026715",
      "title": "Evaluation of New Test Method to Measure Kidney Function",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Kidney Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 150,
      "start_date": "2000-06",
      "completion_date": "2002-06",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-10-15T16:27:06.470Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00026715"
    },
    {
      "nct_id": "NCT05319990",
      "title": "Pathogenesis of Kidney Disease in Type 1 Diabetes: a Modern Kidney Biopsy Cohort (The PANDA Study)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Type 1 Diabetes",
        "Diabetic Kidney Disease",
        "Diabetes Complications",
        "Diabetic Nephropathies",
        "Autoimmune Diabetes"
      ],
      "interventions": [
        {
          "name": "Aminohippurate Sodium Inj 20% Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)",
          "type": "DRUG"
        },
        {
          "name": "Iohexol Inj 300 MG/ML Diagnostic aid/agent used to measure glomerular filtration rate (GFR)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2022-03-09",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-10-15T16:27:06.470Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05319990"
    },
    {
      "nct_id": "NCT03390790",
      "title": "Lidocaine for Pain After Urodynamic Testing",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Voiding Disorders",
        "Overactive Bladder",
        "Urinary Incontinence"
      ],
      "interventions": [
        {
          "name": "Lidocaine gel 2%",
          "type": "DRUG"
        },
        {
          "name": "Standard lubricant gel",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Atlantic Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 80 Years · Female only"
      },
      "enrollment_count": 134,
      "start_date": "2018-01-25",
      "completion_date": "2019-03-29",
      "has_results": false,
      "last_update_posted_date": "2019-07-19",
      "last_synced_at": "2026-10-15T16:27:06.470Z",
      "location_count": 1,
      "location_summary": "Morristown, New Jersey",
      "locations": [
        {
          "city": "Morristown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03390790"
    },
    {
      "nct_id": "NCT04648826",
      "title": "Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Sarcomas",
        "Melanomas",
        "Germ Cell Tumors",
        "Epithelial Malignancies (Excluding Lung and Renal Cell Carcinomas)",
        "Pulmonary Metastases"
      ],
      "interventions": [
        {
          "name": "AeroEclipse II Breath Actuated Nebulizer",
          "type": "DEVICE"
        },
        {
          "name": "Bintrafusp alfa",
          "type": "DRUG"
        },
        {
          "name": "Azacytidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-12-14",
      "completion_date": "2021-12-14",
      "has_results": false,
      "last_update_posted_date": "2021-12-17",
      "last_synced_at": "2026-10-15T16:27:06.470Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04648826"
    },
    {
      "nct_id": "NCT02262455",
      "title": "Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Endometrial Cancer",
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "STM 434",
          "type": "DRUG"
        },
        {
          "name": "Liposomal doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santa Maria Biotherapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2014-10",
      "completion_date": "2017-01-13",
      "has_results": false,
      "last_update_posted_date": "2017-02-13",
      "last_synced_at": "2026-10-15T16:27:06.470Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • New York, New York • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02262455"
    },
    {
      "nct_id": "NCT02740985",
      "title": "A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Malignancies",
        "Non-Small Cell Lung Cancer (NSCLC)",
        "Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)",
        "Colorectal Carcinoma (CRC)"
      ],
      "interventions": [
        {
          "name": "AZD4635",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Oleclumab",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 313,
      "start_date": "2016-06-17",
      "completion_date": "2023-03-31",
      "has_results": false,
      "last_update_posted_date": "2023-05-26",
      "last_synced_at": "2026-10-15T16:27:06.470Z",
      "location_count": 17,
      "location_summary": "Fayetteville, Arkansas • Fresno, California • Denver, Colorado + 14 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02740985"
    },
    {
      "nct_id": "NCT03179410",
      "title": "PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Avelumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Andrew J. Armstrong, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 15,
      "start_date": "2018-02-01",
      "completion_date": "2020-12-18",
      "has_results": true,
      "last_update_posted_date": "2021-03-05",
      "last_synced_at": "2026-10-15T16:27:06.470Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03179410"
    },
    {
      "nct_id": "NCT00158860",
      "title": "A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Herpes Genitalis"
      ],
      "interventions": [
        {
          "name": "Valaciclovir",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 384,
      "start_date": "2004-06-21",
      "completion_date": "2006-07-26",
      "has_results": true,
      "last_update_posted_date": "2019-02-15",
      "last_synced_at": "2026-10-15T16:27:06.470Z",
      "location_count": 58,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00158860"
    }
  ]
}